Efavirenz

Common brands: Epivir, Lamivudine, Viread, Retrovir, Zidovudine

Top reporter: Aurobindo Pharma Limited

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]Protease Inhibitor [EPC]Cytochrome P450 3A Inhibitor [EPC]
11,033
Total Reports
3,364
Serious Reports
1,527
Death Reports
30
Reported Reactions
Death Report Ratio: High (13.84%)

Patient Demographics

Male
4,670
Female
2,852

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Efavirenz.

# Reaction Reports % of Total
1 VIROLOGIC FAILURE 954
8.4%
2 DRUG INTERACTION 758
6.7%
3 DRUG RESISTANCE 735
6.5%
4 VIRAL MUTATION IDENTIFIED 674
6.0%
5 PATHOGEN RESISTANCE 623
5.5%
6 FOETAL EXPOSURE DURING PREGNANCY 613
5.4%
7 DEPRESSION 458
4.1%
8 TREATMENT FAILURE 423
3.7%
9 MATERNAL EXPOSURE DURING PREGNANCY 417
3.7%
10 ANAEMIA 409
3.6%
11 PYREXIA 380
3.4%
12 IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 377
3.3%
13 VOMITING 348
3.1%
14 DEATH 338
3.0%
15 DIARRHOEA 302
2.7%
16 ABORTION SPONTANEOUS 294
2.6%
17 NAUSEA 279
2.5%
18 IMMUNE RECONSTITUTION SYNDROME 278
2.5%
19 DRUG INEFFECTIVE 265
2.3%
20 TREATMENT NONCOMPLIANCE 257
2.3%
21 RENAL IMPAIRMENT 241
2.1%
22 EXPOSURE DURING PREGNANCY 240
2.1%
23 LIPODYSTROPHY ACQUIRED 230
2.0%
24 RASH 228
2.0%
25 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 216
1.9%
26 ALANINE AMINOTRANSFERASE INCREASED 212
1.9%
27 NEUROTOXICITY 195
1.7%
28 OFF LABEL USE 187
1.7%
29 ASTHENIA 182
1.6%
30 ASPARTATE AMINOTRANSFERASE INCREASED 180
1.6%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.